Martin Edwards

Novo Ventures
Senior Partner

Dr Edwards joined Novo A/S in 2003 working out of the UK. He is chairman of the Board of Directors of Epsilon-3 Bio Ltd., and Vantia Therapeutics Ltd., and a member of the Board of Directors of Acacia Pharma Ltd., Karus Therapeutics Ltd., Nuvelution Pharma, Inc., Tarsa Therapeutics Inc., Verona Pharma and F2G.  Dr Edwards also holds an adjunct professorship at Copenhagen Business School (CBS SIMI).

From 1998-2003, Dr Edwards was the CEO of ReNeuron Holdings, taking that company public in 2000 and raising a total of £25m in equity and debt financing. From 1994-1998, he was Corporate V.P and Head of Drug Development for Novo Nordisk A/S where he was responsible for all aspects of pre-clinical and clinical drug development. Previously, he worked for six years in the USA first as V.P Pharmacology and Medical Affairs of ZymoGenetics Inc. in Seattle, and then as Senior V.P for Medical Affairs at Novo Nordisk in Princeton NJ.

Dr Edwards trained in physiology and medicine in Manchester. He is a Member of the Royal Colleges of Physicians, a Member with distinction of the Royal College of General Practitioners, a Fellow of the Faculty of Pharmaceutical Medicine and holds an MBA from the University of Warwick.

Novo Holdings uses cookies to ensure that we give you the best experience on our website. Read more